{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:28:31Z","timestamp":1784240911577,"version":"3.55.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>It has been demonstrated that luteal phase support (LPS) is crucial in filling the gap between the disappearance of exogenously administered hCG for ovulation triggering and the initiation of secretion of endogenous hCG from the implanting conceptus. LPS has a pivotal role of in establishing and maintaining in vitro fertilization (IVF) pregnancies. Over the last decade, a plethora of studies bringing new information on many aspects of LPS have been published. Due to lack of consent between researchers and a dearth of robust evidence-based guidelines, we wanted to make the leap from the bench to the bedside, what are the common LPS practices in fresh IVF cycles compared to current evidence and guidelines? How has expert opinion changed over 10\u00a0years in light of recent literature?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Over a decade (2009\u20132019), we conducted 4 web-based surveys on a large IVF-specialist website on common LPS practices and controversies. The self-report, multiple-choice surveys quantified results by annual IVF cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>On average, 303 IVF units responded to each survey, representing, on average, 231,000 annual IVF cycles. Most respondents in 2019 initiated LPS on the day of, or the day after egg collection (48.7\u2009% and 36.3\u2009%, respectively). In 2018, 72\u2009% of respondents administered LPS for 8\u201310 gestational weeks, while in 2019, 65\u2009% continued LPS until 10\u201312 weeks. Vaginal progesterone is the predominant delivery route; its utilization rose from 64\u2009% of cycles in 2009 to 74.1\u2009% in 2019. Oral P use has remained negligible; a slight increase to 2.9\u2009% in 2019 likely reflects dydrogesterone\u2019s introduction into practice. E2 and GnRH agonists are rarely used for LPS, as is hCG alone, limited by its associated risk of ovarian hyperstimulation syndrome (OHSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our Assisted reproductive technology (ART)-community survey series gave us insights into physician views on using progesterone for LPS. Despite extensive research and numerous publications, evidence quality and recommendation levels are surprisingly low for most topics. Clinical guidelines use mostly low-quality evidence. There is no single accepted LPS protocol. Our study highlights the gaps between science and practice and the need for further LPS research, with an emphasis on treatment individualization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12958-021-00696-2","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T01:02:54Z","timestamp":1611622974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A 10-year follow\u2010up on the practice of luteal phase support using worldwide web\u2010based surveys"],"prefix":"10.1186","volume":"19","author":[{"given":"Gon","family":"Shoham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,26]]},"reference":[{"key":"696_CR1","doi-asserted-by":"crossref","unstructured":"Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P. An update of luteal phase support in stimulated IVF cycles. Hum Reprod Update. 2007;13(6)(1):581\u201390.","DOI":"10.1093\/humupd\/dmm021"},{"issue":"4","key":"696_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3109\/09513599609012319","volume":"10","author":"A Weissiman","year":"1996","unstructured":"Weissiman A, Lurie S, Zalel Y, Goldchmit R, Shoham Z. Human chorionic gonadotropin: pharmacokinetics of subcutaneous administration. Gynecological Endocrinology. 1996;10(4):273\u20136.","journal-title":"Gynecological Endocrinology."},{"issue":"5","key":"696_CR3","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/oxfordjournals.humrep.a019329","volume":"11","author":"A Weissman","year":"1996","unstructured":"Weissman A, Loumaye E, Shoham Z. Recovery of corpus luteum function after prolonged deprivation from gonadotrophin stimulation. Hum Reprod. 1996;11(5):943\u20139.","journal-title":"Hum Reprod."},{"key":"696_CR4","doi-asserted-by":"crossref","unstructured":"Soliman S, Daya MBS, Collins J, Hughes EG. The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials *. Fertil Steril. 1994;61(6)(1):1068\u201376.","DOI":"10.1016\/S0015-0282(16)56758-2"},{"key":"696_CR5","doi-asserted-by":"crossref","unstructured":"Fauser BCJM, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends in Endocrinology Metabolism. 2003;14(5)(1):236\u201342.","DOI":"10.1016\/S1043-2760(03)00075-4"},{"key":"696_CR6","doi-asserted-by":"crossref","unstructured":"Ovarian Stimulation for IVF\/ICSI [Internet]. 2019 [cited 2020 Mar 3]. Available from: https:\/\/www.eshre.eu\/Guidelines-and-Legal\/Guidelines\/Ovarian-Stimulation-in-IVF-ICSI.","DOI":"10.1093\/hropen\/hoaa009"},{"key":"696_CR7","doi-asserted-by":"publisher","unstructured":"Linden M van der, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews [Internet]. 2015 [cited 2020 Mar 8];(7). Available from: https:\/\/www.cochranelibrary.com\/cdsr\/doi\/https:\/\/doi.org\/10.1002\/14651858.CD009154.pub3\/full.","DOI":"10.1002\/14651858.CD009154.pub3\/full"},{"key":"696_CR8","doi-asserted-by":"crossref","unstructured":"Shoham G, Leong M, Weissman A, Yaron Y. Can We Learn from the\u201cWisdom of the Crowd\u201d? Finding the Sample-Size Sweet Spot \u2013 an Analysis of Internet-Based Crowdsourced Surveys of Fertility Professionals. Journal of Medical Statistics Informatics. 2019;30(1):3. 7(.","DOI":"10.7243\/2053-7662-7-3"},{"key":"696_CR9","unstructured":"Progesterone Support In IVF - IVF-Worldwide [Internet]. IVF-Worldwide. 2009 [cited 2020 Jun 15]. Available from: https:\/\/ivf-worldwide.com\/survey\/progesterone-support-in-ivf.html."},{"key":"696_CR10","unstructured":"An updated survey on the use of progesterone for. luteal phase support in stimulated IVF cycles - IVF-Worldwide [Internet]. IVF-Worldwide. 2012 [cited 2020 Jun 15]. Available from: https:\/\/ivf-worldwide.com\/survey\/an-updated-survey-on-the-use-of-progesterone-for-luteal-phase-support-in-stimulated-ivf-cycles.html."},{"key":"696_CR11","unstructured":"A survey on luteal-phase. progesterone support - IVF-Worldwide [Internet]. IVF-Worldwide. 2018 [cited 2020 Jun 15]. Available from: https:\/\/ivf-worldwide.com\/survey\/a-survey-on-luteal-phase-progesterone-support.html."},{"key":"696_CR12","unstructured":"A follow-up survey on luteal-phase progesterone support - IVF-Worldwide [Internet]. IVF-Worldwide. 2019 [cited 2020 Jun 15]. Available from: https:\/\/ivf-worldwide.com\/survey\/a-follow-up-survey-on-luteal-phase-progesterone-support.html."},{"issue":"2","key":"696_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.rbmo.2012.04.005","volume":"25","author":"E Vaisbuch","year":"2012","unstructured":"Vaisbuch E, Leong M, Shoham Z. Progesterone support in IVF: is evidence-based medicine translated to clinical practice? A worldwide web-based survey. Reproductive BioMedicine Online. 2012;25(2):139\u201345.","journal-title":"Reproductive BioMedicine Online."},{"key":"696_CR14","doi-asserted-by":"crossref","unstructured":"Shoham G, Levy-Toledano R, Leong M, Weissman A, Yaron Y, Shoham Z. Oncofertility: insights from IVF specialists\u2014a worldwide web-based survey analysis. J Assist Reprod Genet. 2019;20(5):1013\u201321. 36(.","DOI":"10.1007\/s10815-019-01419-8"},{"key":"696_CR15","doi-asserted-by":"crossref","unstructured":"Weissman A, Shoham G, Shoham Z, Fishel S, Leong M, Yaron Y. Preimplantation genetic screening: results of a worldwide web-based survey. Reproductive BioMedicine Online. 2017;35(6)(1):693\u2013700.","DOI":"10.1016\/j.rbmo.2017.09.001"},{"issue":"5","key":"696_CR16","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.fertnstert.2017.02.119","volume":"107","author":"A Weissman","year":"2017","unstructured":"Weissman A, Shoham G, Shoham Z, Fishel S, Leong M, Yaron Y. Chromosomal mosaicism detected during preimplantation genetic screening: results of a worldwide Web-based survey. Fertility and Sterility. 2017;107(5):1092\u20137.","journal-title":"Fertility and Sterility."},{"issue":"5","key":"696_CR17","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.fertnstert.2018.03.006","volume":"109","author":"D de Ziegler","year":"2018","unstructured":"de Ziegler D, Pirtea P, Andersen CY, Ayoubi JM. Role of gonadotropin-releasing hormone agonists, human chorionic gonadotropin (hCG), progesterone, and estrogen in luteal phase support after hCG triggering, and when in pregnancy hormonal support can be stopped. Fertility and Sterility. 2018;109(5):749\u201355.","journal-title":"Fertility and Sterility."},{"issue":"12","key":"696_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1023\/B:JARG.0000013653.54830.2c","volume":"20","author":"R Baruffi","year":"2003","unstructured":"Baruffi R, Mauri AL, Petersen CG, Felipe V, Franco JG. Effects of Vaginal Progesterone Administration Starting on the Day of Oocyte Retrieval on Pregnancy Rates. J Assist Reprod Genet. 2003;20(12):517\u201320.","journal-title":"J Assist Reprod Genet."},{"issue":"6","key":"696_CR19","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/S0015-0282(01)01787-3","volume":"75","author":"R Fanchin","year":"2001","unstructured":"Fanchin R, Righini C, de Ziegler D, Olivennes F, Led\u00e9e N, Frydman R. Effects of vaginal progesterone administration on uterine contractility at the time of embryo transfer. Fertility and Sterility. 2001;75(6):1136\u201340.","journal-title":"Fertility and Sterility."},{"issue":"4","key":"696_CR20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/humrep\/dei437","volume":"21","author":"MH Mochtar","year":"2006","unstructured":"Mochtar MH, Van Wely M, Van der Veen F. Timing luteal phase support in GnRH agonist down-regulated IVF\/embryo transfer cycles. Hum Reprod. 2006;21(4):905\u20138.","journal-title":"Hum Reprod."},{"issue":"1","key":"696_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0015-0282(98)00404-X","volume":"71","author":"SH Sohn","year":"1999","unstructured":"Sohn SH, Penzias AS, Emmi AM, Dubey AK, Layman LC, Reindollar RH, et al. Administration of progesterone before oocyte retrieval negatively affects the implantation rate. Fertility and Sterility. 1999;71(1):11\u20134.","journal-title":"Fertility and Sterility."},{"issue":"1","key":"696_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.fertnstert.2017.09.033","volume":"109","author":"J Gao","year":"2018","unstructured":"Gao J, Gu F, Miao B-Y, Chen M-H, Zhou C-Q, Xu Y-W. Effect of the initiation of progesterone supplementation in in vitro fertilization\u2013embryo transfer outcomes: a prospective randomized controlled trial. Fertility and Sterility. 2018;109(1):97\u2013103.","journal-title":"Fertility and Sterility."},{"issue":"6","key":"696_CR23","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/S0015-0282(01)02914-4","volume":"76","author":"SC Williams","year":"2001","unstructured":"Williams SC, Oehninger S, Gibbons WE, Van Cleave WC, Muasher SJ. Delaying the initiation of progesterone supplementation results in decreased pregnancy rates after in vitro fertilization: a randomized, prospective study. Fertility and Sterility. 2001;76(6):1140\u20133.","journal-title":"Fertility and Sterility."},{"issue":"4","key":"696_CR24","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/humrep\/den012","volume":"23","author":"MA Aboulghar","year":"2008","unstructured":"Aboulghar MA, Amin YM, Al-Inany HG, Aboulghar MM, Mourad LM, Serour GI, et al. Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks. Hum Reprod. 2008;23(4):857\u201362.","journal-title":"Hum Reprod."},{"issue":"3","key":"696_CR25","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.fertnstert.2009.05.003","volume":"94","author":"CS Goudge","year":"2010","unstructured":"Goudge CS, Nagel TC, Damario MA. Duration of progesterone-in-oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial. Fertility and Sterility. 2010;94(3):946\u201351.","journal-title":"Fertility and Sterility."},{"issue":"4","key":"696_CR26","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.fertnstert.2012.05.046","volume":"98","author":"G Kohls","year":"2012","unstructured":"Kohls G, Ruiz F, Mart\u00ednez M, Hauzman E, de la Fuente G, Pellicer A, et al. Early progesterone cessation after in vitro fertilization\/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility. 2012;98(4):858\u201362.","journal-title":"Fertility and Sterility."},{"issue":"5","key":"696_CR27","first-page":"1020","volume":"26","author":"D Kyrou","year":"2011","unstructured":"Kyrou D, Fatemi HM, Zepiridis L, Riva A, Papanikolaou EG, Tarlatzis BC, et al. Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH\/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial Hum Reprod. 2011;26(5):1020\u20134.","journal-title":"A randomized controlled trial. Hum Reprod."},{"issue":"2","key":"696_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/humrep\/17.2.357","volume":"17","author":"A Nyboe Andersen","year":"2002","unstructured":"Nyboe Andersen A, Popovic-Todorovic B, Schmidt KT, Loft A, Lindhard A, H\u00f8jgaard A, et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Hum Reprod. 2002;17(2):357\u201361.","journal-title":"Hum Reprod."},{"key":"696_CR29","doi-asserted-by":"crossref","unstructured":"Prietl G, Diedrich K, van der Ven HH, Luckhaus J, Krebs D. The effect of 17\u03b1-hydroxyprogesterone caproate\/oestradiol valerate on the development and outcome of early pregnancies following in vitro fertilization and embryo transfer: A prospective and randomized controlled trail. Hum Reprod. 1992;7(suppl_1):1\u20135.","DOI":"10.1093\/humrep\/7.suppl_1.1"},{"issue":"1","key":"696_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1745-6215-13-118","volume":"13","author":"R Gazvani","year":"2012","unstructured":"Gazvani R, Russell R, Sajjad Y, Alfirevic Z. Duration of luteal support (DOLS) with progesterone pessaries to improve the success rates in assisted conception: study protocol for a randomized controlled trial. Trials. 2012;13(1):118.","journal-title":"Trials."},{"issue":"1","key":"696_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.rbmo.2019.10.009","volume":"40","author":"M Watters","year":"2020","unstructured":"Watters M, Noble M, Child T, Nelson S. Short versus extended progesterone supplementation for luteal phase support in fresh IVF cycles: a systematic review and meta-analysis. Reproductive BioMedicine Online. 2020;40(1):143\u201350.","journal-title":"Reproductive BioMedicine Online."},{"key":"696_CR32","doi-asserted-by":"crossref","unstructured":"Liu X-R, Mu H-Q, Shi Q, Xiao X-Q, Qi H-B. The optimal duration of progesterone supplementation in pregnant women after IVF\/ICSI: a meta-analysis. Reproductive Biology Endocrinology. 2012;13(1):107. 10(.","DOI":"10.1186\/1477-7827-10-107"},{"key":"696_CR33","doi-asserted-by":"crossref","unstructured":"Russell R, Kingsland C, Alfirevic Z, Gazvani R. Duration of luteal support after IVF is important, so why is there no consistency in practice? The results of a dynamic survey of practice in the United Kingdom. Human Fertility. 2015 Jan;18(1)(2):43\u20137.","DOI":"10.3109\/14647273.2014.921337"},{"key":"696_CR34","unstructured":"Abdelhakim AM, Abd-ElGawad M, Hussein RS, Abbas AM. Vaginal versus intramuscular progesterone for luteal phase support in assisted reproductive techniques: a systematic review and meta-analysis of randomized controlled trials. Gynecol Endocrinol. 2020;14(0):1\u20139. 0(."},{"key":"696_CR35","doi-asserted-by":"crossref","unstructured":"Doblinger J, Cometti B, Trevisan S, Griesinger G. Subcutaneous Progesterone Is Effective and Safe for Luteal Phase Support in IVF: An Individual Patient Data Meta-Analysis of the Phase III Trials. PLOS ONE. 2016;18(3):e0151388. 11(.","DOI":"10.1371\/journal.pone.0151388"},{"issue":"5","key":"696_CR36","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/humrep\/12.5.1073","volume":"12","author":"C Bulletti","year":"1997","unstructured":"Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod. 1997;12(5):1073\u20139.","journal-title":"Hum Reprod."},{"issue":"3","key":"696_CR37","first-page":"403","volume":"95","author":"E Cicinelli","year":"2000","unstructured":"Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstetrics & Gynecology. 2000;95(3):403\u20136.","journal-title":"Obstetrics & Gynecology."},{"key":"696_CR38","doi-asserted-by":"crossref","unstructured":"Child T, Leonard SA, Evans JS, Lass A. Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles. Reproductive BioMedicine Online. 2018;36(6)(1):630\u201345.","DOI":"10.1016\/j.rbmo.2018.02.001"},{"key":"696_CR39","doi-asserted-by":"crossref","unstructured":"Licciardi FL, Kwiatkowski A, Noyes NL, Berkeley AS, Krey LL, Grifo JA. Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertil Steril. 1999;71(4)(1):614\u20138.","DOI":"10.1016\/S0015-0282(98)00515-9"},{"issue":"8","key":"696_CR40","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/humrep\/14.8.1944","volume":"14","author":"S Friedler","year":"1999","unstructured":"Friedler S, Raziel A, Schachter M, Strassburger D, Bukovsky I, Ron-El R. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration. Hum Reprod. 1999;14(8):1944\u20138.","journal-title":"Hum Reprod."},{"issue":"11","key":"696_CR41","first-page":"527","volume":"19","author":"J Buvat","year":"1990","unstructured":"Buvat J, Marcolin G, Guittard C, Dehaene J, Herbaut J, Louvet A. Luteal support after administration of an LHRH analog for in vitro fertilization. Superiority of vaginal progesterone in comparison with oral progesterone. Presse Med. 1990;19(11):527.","journal-title":"Presse Med"},{"issue":"3","key":"696_CR42","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0015-0282(99)00553-1","volume":"73","author":"H Levine","year":"2000","unstructured":"Levine H, Watson N. Comparison of the pharmacokinetics of crinone 8\u2009% administered vaginally versus Prometrium administered orally in postmenopausal women(3). Fertil Steril. 2000;73(3):516\u201321.","journal-title":"Fertil Steril"},{"issue":"3","key":"696_CR43","first-page":"188","volume":"34","author":"P Devroey","year":"1989","unstructured":"Devroey P, Palermo G, Bourgain C, Van Waesberghe L, Smitz J, Van Steirteghem AC. Progesterone administration in patients with absent ovaries. Int J Fertil. 1989;34(3):188\u201393.","journal-title":"Int J Fertil"},{"issue":"5","key":"696_CR44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/oxfordjournals.humrep.a137138","volume":"5","author":"C Bourgain","year":"1990","unstructured":"Bourgain C, Devroey P, Van Waesberghe L, Smitz J, Van Steirteghem AC. Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum Reprod. 1990;5(5):537\u201343.","journal-title":"Hum Reprod"},{"key":"696_CR45","doi-asserted-by":"crossref","unstructured":"Barbosa MWP, Valadares NPB, Barbosa ACP, Amaral AS, Iglesias JR, Nastri CO, et al. Oral dydrogesterone vs. vaginal progesterone capsules for luteal-phase support in women undergoing embryo transfer: a systematic review and meta-analysis. JBRA Assist Reprod. 2018;22(2):148\u201356.","DOI":"10.5935\/1518-0557.20180018"},{"key":"696_CR46","doi-asserted-by":"crossref","unstructured":"Griesinger G, Blockeel C, Sukhikh GT, Patki A, Dhorepatil B, Yang D-Z, et al. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018;01(12):2212\u201321. 33(.","DOI":"10.1093\/humrep\/dey306"},{"issue":"4","key":"696_CR47","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0015-0282(99)00632-9","volume":"73","author":"J Farhi","year":"2000","unstructured":"Farhi J, Weissman A, Steinfeld Z, Shorer M, Nahum H, Levran D. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertility and Sterility. 2000;73(4):761\u20136.","journal-title":"Fertility and Sterility."},{"issue":"5","key":"696_CR48","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.fertnstert.2004.11.055","volume":"83","author":"K Lukaszuk","year":"2005","unstructured":"Lukaszuk K, Liss J, Lukaszuk M, Maj B. Optimization of estradiol supplementation during the luteal phase improves the pregnancy rate in women undergoing in vitro fertilization\u2013embryo transfer cycles. Fertility and Sterility. 2005;83(5):1372\u20136.","journal-title":"Fertility and Sterility."},{"issue":"12","key":"696_CR49","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3109\/09513590.2014.964638","volume":"30","author":"S Gizzo","year":"2014","unstructured":"Gizzo S, Andrisani A, Esposito F, Noventa M, Di Gangi S, Angioni S, et al. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial. Gynecol Endocrinol. 2014;30(12):902\u20138.","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"696_CR50","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejogrb.2010.10.003","volume":"154","author":"E Tonguc","year":"2011","unstructured":"Tonguc E, Var T, Ozyer S, Citil A, Dogan M. Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2011;154(2):172\u20136.","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology."},{"issue":"10","key":"696_CR51","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/humrep\/del117","volume":"21","author":"HM Fatemi","year":"2006","unstructured":"Fatemi HM, Kolibianakis EM, Camus M, Tournaye H, Donoso P, Papanikolaou E, et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist\/rFSH for IVF: a randomized controlled trial. Hum Reprod. 2006;21(10):2628\u201332.","journal-title":"Hum Reprod"},{"issue":"2","key":"696_CR52","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/14647273.2016.1200145","volume":"19","author":"WA Ismail Madkour","year":"2016","unstructured":"Ismail Madkour WA, Noah B, Abdel Hamid AMS, Zaheer H, Al-Bahr A, Shaeer M, et al. Luteal phase support with estradiol and progesterone versus progesterone alone in GnRH antagonist ICSI cycles: a randomized controlled study. Hum Fertil (Camb). 2016;19(2):142\u20139.","journal-title":"Hum Fertil (Camb)"},{"issue":"7","key":"696_CR53","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/humrep\/del072","volume":"21","author":"C Pirard","year":"2006","unstructured":"Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod. 2006;21(7):1894\u2013900.","journal-title":"Hum Reprod"},{"issue":"1","key":"696_CR54","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.fertnstert.2016.10.011","volume":"107","author":"I Bar Hava","year":"2017","unstructured":"Bar Hava I, Blueshtein M, Ganer Herman H, Omer Y, Ben David G. Gonadotropin-releasing hormone analogue as sole luteal support in antagonist-based assisted reproductive technology cycles. Fertil Steril. 2017;107(1):130\u20135.e1.","journal-title":"Fertil Steril"},{"issue":"5","key":"696_CR55","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/09513590.2018.1548591","volume":"35","author":"S Friedler","year":"2019","unstructured":"Friedler S, Grin L. Luteal phase support with GnRH agonist does not eliminate the risk for ovarian hyperstimulation syndrome. Gynecol Endocrinol. 2019;35(5):368\u20139.","journal-title":"Gynecol Endocrinol."},{"issue":"5","key":"696_CR56","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.rbmo.2014.01.012","volume":"28","author":"C Yding Andersen","year":"2014","unstructured":"Yding Andersen C, Vilbour Andersen K. Improving the luteal phase after ovarian stimulation: reviewing new options. Reprod Biomed Online. 2014;28(5):552\u20139.","journal-title":"Reprod Biomed Online"},{"issue":"7","key":"696_CR57","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3109\/09513590.2013.797392","volume":"29","author":"B Sonntag","year":"2013","unstructured":"Sonntag B, Loebbecke KC, Nofer J-R, Kiesel L, Greb RR. Serum estradiol and progesterone in the mid-luteal phase predict clinical pregnancy outcome in IVF\/ICSI cycles. Gynecol Endocrinol. 2013;29(7):700\u20133.","journal-title":"Gynecol Endocrinol"},{"key":"696_CR58","doi-asserted-by":"crossref","unstructured":"Aslih N, Ellenbogen A, Shavit T, Michaeli M, Yakobi D, Shalom-Paz E. Can We Alter Pregnancy Outcome by Adjusting Progesterone Treatment at Mid-Luteal Phase: A Randomized Controlled Trial [Internet]. Vol.\u00a033, Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. Gynecol Endocrinol; 2017 [cited 2020 Apr 19]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28277886\/?from_single_result=Can+we+alter+pregnancy+outcome+by+adjusting+progesterone+treatment+at+mid-luteal+phase%3A+a+randomized+controlled+trial.&expanded_search_query=Can+we+alter+pregnancy+outcome+by+adjusting+progesterone+treatment+at+mid-luteal+phase%3A+a+randomized+controlled+trial.","DOI":"10.1080\/09513590.2017.1298742"},{"issue":"4","key":"696_CR59","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.rbmo.2017.12.019","volume":"36","author":"JF Petersen","year":"2018","unstructured":"Petersen JF, Andersen AN, Klein BM, Helmgaard L, Arce J-C. Luteal phase progesterone and oestradiol after ovarian stimulation: relation to response and prediction of pregnancy. Reprod Biomed Online. 2018;36(4):427\u201334.","journal-title":"Reprod Biomed Online"},{"key":"696_CR60","doi-asserted-by":"crossref","unstructured":"Rajkomar A, Dean J, Kohane I. Machine Learning in Medicine. New England Journal of Medicine. 2019;380(14):1347\u201358.","DOI":"10.1056\/NEJMra1814259"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-021-00696-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12958-021-00696-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-021-00696-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T01:03:32Z","timestamp":1611623012000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-021-00696-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,26]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["696"],"URL":"https:\/\/doi.org\/10.1186\/s12958-021-00696-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-93398\/v1","asserted-by":"object"}]},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,26]]},"assertion":[{"value":"13 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"o The IVF-Worldwide surveys were self-reports on activity volumes and opinions on medical practices from physicians and researchers. The survey conducted and this study did not involve research on human or animal subjects; therefore, institutional review board approval was not required. The survey was conducted as an open-access questionnaire to IVF-Worldwide.com members who voluntarily answered the study questions. no patient\u2019s details were required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"G.S. is a medical advisor at IVF-Worldwide. M.L. is an executive at IVF-Worldwide. A.W. has nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}